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 Glioblastoma is the most common primary malignant 
brain tumor in adults, and is generally incurable.  
The prognosis is poor, with a median survival of only 
13-16 months (Lau).  Aurora-A, a serine-threonine 
kinase critical for a variety of cellular processes 
including centrosome duplication, spindle assembly, 
and mitotic exit, is widely overexpressed in 
glioblastoma.  Additionally, malignant gliomas also 
possess high levels of vascular endothelial growth 
factor (VEGF), which is associated with pathological 
vasculogenesis and angiogenesis.  Therefore, drugs 
that inhibit Aurora-A, in addition to VEGF and its 
receptor, are of interest in order to inhibit 
neovascularization and cellular proliferation.  It was 
hypothesized that combining alisertib with a VEGFR 
inhibitor, such as cabozantinib or vandetanib, would 
work synergistically to inhibit glioblastoma cell 
proliferation and induce cell death via apoptosis.  
The glioblastoma cell lines U87 and U1242 were 
treated with a range of concentrations of alisertib 
and either cabozantinib or vandetanib.  The results 
of these experiments were analyzed using Chou-
Talalay and Bliss Independence models to test for 
synergism.  Because of the lack of effective 
treatments available for glioblastoma, successful 
completion of this study may provide a basis for 
clinical trials including these drug combinations, and 
expand the potential treatment options for this 
aggressive disease. 
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•  The data suggests that alisertib has the ability to 
work synergistically with both cabozantinib and 
vandetanib in glioblastoma cell lines U1242 and 
U87.  
•  The concept that Aurora-A inhibitors used in 
combination with VEGFR inhibitors may be an 
effective glioblastoma treatment is validated by 
these studies at the in vitro level, suggesting that 
further in vivo testing in animal models and 
possibly clinical trials in glioblastoma patients may 
be warranted. 
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Colony Formation Assay 
U87 and U1242 glioblastoma cells were plated at 
600 cells per plate in ninety 60-mm2 plates, then 
incubated for 24 hours at standard conditions.  
Subsequently, cells were treated in the presence of 
drug or sterile water corresponding to the multiples 
of the IC50 of each drug in each cell line; three 
plates were treated per condition.  After three days 
of incubation, plates were washed in PBS to 
remove residual drug, and media was replaced.  
After an additional 3 days of incubation, plates were 
washed with PBS, fixed with methanol, and stained 
with Giemsa stain.  Cells were observed and 
colonies counted via a dissecting microscope.  
Colonies containing 20 cells or more were scored.  
Percent survival was calculated as the number of 
colonies formed in treated plates/number of 
colonies in control untreated plates, and the results 
were graphed using Microsoft Excel software. 
 
Statistical Analysis 
Data expressed as percent survival of cells relative 
to control untreated cells was collected for each 
drug combination over the tested range of 
concentrations.  Synergy is loosely defined as 
exhibiting more potent drug activity at lower dose 
levels when used in combination than when used 
individually at single drug doses (Zhao).  The 
statistical methods for testing for synergism that we 
used include the Chou-Talalay and Bliss 
independence models (Bliss, Chou).   
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•  Both Aurora-A inhibitors and VEGFR inhibitors 
have been shown to possess anti-proliferative 
properties when used individually in glioblastoma 
cells (Van Brocklyn).  
•  In a normal brain, the expression of VEGF and its 
receptor is very low; however, malignant gliomas 
possess elevated amounts of VEGF.  Additionally, 
Aurora-A tends to be widely overexpressed in 
glioblastoma. Therefore, inhibiting these two 
pathways is of interest in our research.  
•  We hypothesized that combining alisertib 
(MLN8237) with a VEGFR inhibitor, such as 
cabozantinib or vandetanib, would result in the 
potentiation of the anti-proliferative effects of 
alisertib in glioblastoma cells. 
Results 
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•  Synergism was observed predominantly in the 
middle dose ranges in each of the drug 
combinations in both cell lines.  
•  Alisertib + Cabozantinib: In the U87 cell line, 
synergism was exhibited in the 0.5x-1x IC50 range.  
In the U1242 cell line, synergism was exhibited in 
the 0.5x-0.75x range.  Both results were observed 
using the Bliss independence model.  
•  Alisertib + Vandetanib: In the U87 cell line, 
synergism was exhibited in the 0.5x-0.75x range.  
In the U1242 cell line, synergism was exhibited in 
the 0.5x-0.75x range.  Both results were observed 
using the Bliss independence model. 
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Figure 2. Colony formation assay results showing percent survival 
of glioblastoma cell lines U87 and U1242. 
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Figure 3. Colony formation assay results of U1242 cells treated with 
alisertib and cabozantinib. From left to right: alisertib + cabozantinib 
0x, cabozantinib 1x, alisertib 1x, alisertib + cabozantinib 2x.  
Figure 1. Pathways regulated by Aurora-A (Lehman, NL).   
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